Boston University
The effect of gluten challenge on gastrointestinal and extraintestinal symptoms in patients diagnosed with Celiac Disease
Abstract
dc:description.abstractCeliac Disease is a disorder that causes immune system activation when a person who is genetically predisposed ingests gluten. This ingestion leads to damage of the villi of the small intestine, often resulting in an inability for the patient to absorb or digest nutrients. In a clinical setting, Celiac Disease most often manifests itself in the form of gastrointestinal and extraintestinal symptoms, but diagnosis is often difficult due to a complex pathogenesis and the need for an intestinal biopsy to confirm. Currently, the only accepted treatment for Celiac Disease is a patient’s adherence to a gluten-free diet, although limitations to this diet exist. Studies have recently been conducted in which patients who are affected by Celiac Disease have been reintroduced to gluten in what is known as a gluten challenge. By doing so, study conductors hope to gain a better understanding of the immune activation and the frequency of symptoms that result from a Celiac Disease patient being exposed to gluten. This meta-analysis looks at these studies, where pooled analyses for the frequency of symptoms were completed across randomized controlled trials and nonrandomized controlled trials. The overall analysis across randomized controlled trials found the frequency of nausea, vomiting, bloating, and abdominal pain to have proportions that were above 0.25, and, as a result, may be considered significant side effects of gluten ingestion. As for the pooled analysis across all observational studies the frequency of abdominal pain was the only symptom with a proportion above 0.25. Nausea, diarrhea, and bloating, however, had proportions that were just below the 0.25 threshold. This work establishes the baseline proportion of symptoms during a gluten challenge in order to help normalize adverse events that may occur in therapeutic trials involving a gluten challenge and with experimental drugs being tested in Celiac Disease.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Grantor
- Boston University
- Year dc:date.issued
- 2022
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Simpson, Amelia
- Advisor dc:contributor.advisor
-
- Traber, Katrina
Subjects
dc:subject × 3Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53531